149 related articles for article (PubMed ID: 16390814)
21. The first step into the brain: uptake of NIO-PBCA nanoparticles by endothelial cells in vitro and in vivo, and direct evidence for their blood-brain barrier permeation.
Weiss CK; Kohnle MV; Landfester K; Hauk T; Fischer D; Schmitz-Wienke J; Mailänder V
ChemMedChem; 2008 Sep; 3(9):1395-403. PubMed ID: 18613205
[TBL] [Abstract][Full Text] [Related]
22. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles.
Wilson B; Samanta MK; Santhi K; Kumar KP; Paramakrishnan N; Suresh B
Eur J Pharm Biopharm; 2008 Sep; 70(1):75-84. PubMed ID: 18472255
[TBL] [Abstract][Full Text] [Related]
23. [The delivery of loperamide to the brain by using polybutyl cyanoacrylate nanoparticles].
Aliautdin RN; Petrov VE; Langer K; Berthold A; Kreuter J; Kharkevich DA
Eksp Klin Farmakol; 1998; 61(1):17-20. PubMed ID: 9575405
[TBL] [Abstract][Full Text] [Related]
24. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles.
Kurakhmaeva KB; Djindjikhashvili IA; Petrov VE; Balabanyan VU; Voronina TA; Trofimov SS; Kreuter J; Gelperina S; Begley D; Alyautdin RN
J Drug Target; 2009 Sep; 17(8):564-74. PubMed ID: 19694610
[TBL] [Abstract][Full Text] [Related]
25. A Comparative Study of Orally Delivered PBCA and ApoE Coupled BSA Nanoparticles for Brain Targeting of Sumatriptan Succinate in Therapeutic Management of Migraine.
Girotra P; Singh SK
Pharm Res; 2016 Jul; 33(7):1682-95. PubMed ID: 27003706
[TBL] [Abstract][Full Text] [Related]
26. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.
Kreuter J; Shamenkov D; Petrov V; Ramge P; Cychutek K; Koch-Brandt C; Alyautdin R
J Drug Target; 2002 Jun; 10(4):317-25. PubMed ID: 12164380
[TBL] [Abstract][Full Text] [Related]
27. Nanoparticulate systems for brain delivery of drugs.
Kreuter J
Adv Drug Deliv Rev; 2001 Mar; 47(1):65-81. PubMed ID: 11251246
[TBL] [Abstract][Full Text] [Related]
28. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity.
Olivier JC; Fenart L; Chauvet R; Pariat C; Cecchelli R; Couet W
Pharm Res; 1999 Dec; 16(12):1836-42. PubMed ID: 10644071
[TBL] [Abstract][Full Text] [Related]
29. Nanotoxicity of poly(n-butylcyano-acrylate) nanoparticles at the blood-brain barrier, in human whole blood and in vivo.
Kolter M; Ott M; Hauer C; Reimold I; Fricker G
J Control Release; 2015 Jan; 197():165-79. PubMed ID: 25445700
[TBL] [Abstract][Full Text] [Related]
30. Polybutylcyanoacrylate nanoparticles as a carrier for mitomycin C in rabbits bearing VX2-liver tumor.
Xi-Xiao Y; Jan-Hai C; Shi-Ting L; Dan G; Xv-Xin Z
Regul Toxicol Pharmacol; 2006 Dec; 46(3):211-7. PubMed ID: 17010489
[TBL] [Abstract][Full Text] [Related]
31. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles.
Gao K; Jiang X
Int J Pharm; 2006 Mar; 310(1-2):213-9. PubMed ID: 16426779
[TBL] [Abstract][Full Text] [Related]
32. Body distribution of 3H-labelled dalargin bound to poly(butyl cyanoacrylate) nanoparticles after i.v. injections to mice.
Schroeder U; Schroeder H; Sabel BA
Life Sci; 2000; 66(6):495-502. PubMed ID: 10794066
[TBL] [Abstract][Full Text] [Related]
33. In vitro and in vivo evaluation of 10-hydroxycamptothecin-loaded poly (n-butyl cyanoacrylate) nanoparticles prepared by miniemulsion polymerization.
Jin X; Asghar S; Zhu X; Chen Z; Tian C; Yin L; Ping Q; Xiao Y
Colloids Surf B Biointerfaces; 2018 Feb; 162():25-34. PubMed ID: 29145001
[TBL] [Abstract][Full Text] [Related]
34. Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model.
Wang CX; Huang LS; Hou LB; Jiang L; Yan ZT; Wang YL; Chen ZL
Brain Res; 2009 Mar; 1261():91-9. PubMed ID: 19401168
[TBL] [Abstract][Full Text] [Related]
35. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study.
Alyautdin RN; Tezikov EB; Ramge P; Kharkevich DA; Begley DJ; Kreuter J
J Microencapsul; 1998; 15(1):67-74. PubMed ID: 9463808
[TBL] [Abstract][Full Text] [Related]
36. Effects of apolipoproteins on dalargin transport across the blood-brain barrier.
Shamenkov DA; Petrov VE; Alyautdin RN
Bull Exp Biol Med; 2006 Dec; 142(6):703-6. PubMed ID: 17603675
[TBL] [Abstract][Full Text] [Related]
37. Intravenous tolerance of a nanoparticle-based formulation of doxorubicin in healthy rats.
Pereverzeva E; Treschalin I; Bodyagin D; Maksimenko O; Kreuter J; Gelperina S
Toxicol Lett; 2008 Apr; 178(1):9-19. PubMed ID: 18374523
[TBL] [Abstract][Full Text] [Related]
38. Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: focus on cardio- and testicular toxicity.
Pereverzeva E; Treschalin I; Bodyagin D; Maksimenko O; Langer K; Dreis S; Asmussen B; Kreuter J; Gelperina S
Int J Pharm; 2007 Jun; 337(1-2):346-56. PubMed ID: 17306479
[TBL] [Abstract][Full Text] [Related]
39. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles.
Duan J; Mansour HM; Zhang Y; Deng X; Chen Y; Wang J; Pan Y; Zhao J
Int J Pharm; 2012 Apr; 426(1-2):193-201. PubMed ID: 22274587
[TBL] [Abstract][Full Text] [Related]
40. Polybutylcyanoacrylate magnetic nanoparticles as carriers of adriamycin.
Cai L; Niu G; Hu Z; Jin W; Wang J; Sun L
J Drug Target; 2009 Apr; 17(3):200-6. PubMed ID: 19558359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]